8-K Announcements
6Material company update
Apr 10, 2026·SEC
Material company update
Apr 1, 2026·SEC
Material company update
Feb 20, 2026·SEC
Bruker Corporation(BRKR)Earnings, Financials & Key Ratios
BRKR•NASDAQ
$38.01
$5.77B mkt cap·50.0× P/E·Price updated May 6, 2026
AboutBruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.Show more
- Revenue$3.37B+13.6%
- EBITDA$437M-20.8%
- Net Income$113M-73.5%
- EPS (Diluted)0.76-73.8%
- Gross Margin49%-4.0%
- EBITDA Margin12.98%-30.3%
- Operating Margin7.52%-49.0%
- Net Margin3.36%-76.7%
- ROE7.01%-79.1%
- ROIC6.14%-61.9%
- Debt/Equity1.24+26.7%
- Interest Coverage5.28-80.2%
BRKR Key Insights
Bruker Corporation (BRKR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 22.4%
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 10.2%
✗Weaknesses
- ✗Profits declining 10.5% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BRKR Price & Volume
Bruker Corporation (BRKR) stock price & volume — 10-year historical chart
Loading chart...
BRKR Growth Metrics
Bruker Corporation (BRKR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years6.41%
5 Years10.19%
3 Years11.66%
TTM2.08%
Profit CAGR
10 Years7.15%
5 Years-10.52%
3 Years-25.82%
TTM-107.6%
EPS CAGR
10 Years8.7%
5 Years-9.62%
3 Years-25.12%
TTM-120%
Return on Capital
10 Years14.22%
5 Years13.17%
3 Years12.63%
Last Year6.68%
BRKR Recent Earnings
Bruker Corporation (BRKR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)
Q1 2026Latest
Feb 12, 2026EPS
$0.59
Est $0.65
-9.2%
Revenue
$977M
Est $962M
+1.6%
Q4 2025
Nov 3, 2025EPS
$0.60
Est $0.33
+81.8%
Revenue
$861M
Est $965M
-10.8%
Q3 2025
Aug 4, 2025EPS
$0.32
Est $0.33
-3.0%
Revenue
$797M
Est $810M
-1.6%
Q2 2025
May 7, 2025EPS
$0.47
Est $0.46
+2.2%
Revenue
$801M
Est $820M
-2.3%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 12, 2026 | $0.59vs $0.65-9.2% | $977Mvs $962M+1.6% |
| Q4 2025 | Nov 3, 2025 | $0.60vs $0.33+81.8% | $861Mvs $965M-10.8% |
| Q3 2025 | Aug 4, 2025 | $0.32vs $0.33-3.0% | $797Mvs $810M-1.6% |
| Q2 2025 | May 7, 2025 | $0.47vs $0.46+2.2% | $801Mvs $820M-2.3% |
Based on last 12 quarters of dataView full earnings history →
BRKR Peer Comparison
Bruker Corporation (BRKR) competitors in Imaging, radiation, and oncology devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 WAT | 20.38B | 342.53 | 31.83 | 6.99% | 11.91% | 8.04% | 2.65% | 0.55 |
 TRMB | 16.27B | 68.37 | 39.07 | -2.61% | 11.82% | 7.27% | 0.82% | 0.24 |
 FTV | 18.68B | 60.69 | 34.88 | -17.48% | 11.48% | 7.38% | 5.24% | 0.50 |
 A | 33.27B | 117.53 | 25.72 | 6.73% | 18.26% | 18.67% | 3.46% | 0.50 |
 TMO | 173.46B | 466.76 | 26.31 | 3.91% | 15.18% | 13.23% | 3.63% | 0.76 |
 MTD | 26.47B | 1302.42 | 30.89 | 3.98% | 21.59% | 3.21% | ||
 ROP | 36.7B | 356.56 | 25.11 | 12.26% | 21.12% | 8.75% | 6.79% | 0.47 |
 DHR | 123.6B | 174.63 | 34.65 | 2.9% | 14.89% | 7.06% | 4.26% | 0.35 |
Compare BRKR vs Peers
Bruker Corporation (BRKR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BRKR Income Statement
Bruker Corporation (BRKR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.61B | 1.77B | 1.9B | 2.07B | 1.99B | 2.42B | 2.53B | 2.96B | 3.37B | 3.44B |
| Revenue Growth % | -0.77% | 9.59% | 7.34% | 9.34% | -4.11% | 21.66% | 4.67% | 17.14% | 13.56% | 2.08% |
| Cost of Goods Sold | 868.8M | 952.9M | 995.6M | 1.08B | 1.05B | 1.21B | 1.23B | 1.45B | 1.72B | 1.83B |
| COGS % of Revenue | 53.92% | 53.96% | 52.52% | 51.98% | 52.71% | 49.97% | 48.41% | 48.95% | 51% | - |
| Gross Profit | 742.5M▲ 0% | 813M▲ 9.5% | 900M▲ 10.7% | 995.3M▲ 10.6% | 939.8M▼ 5.6% | 1.21B▲ 28.7% | 1.31B▲ 7.9% | 1.51B▲ 15.9% | 1.65B▲ 9.0% | 1.6B▲ 0% |
| Gross Margin % | 46.08% | 46.04% | 47.48% | 48.02% | 47.29% | 50.03% | 51.59% | 51.05% | 49% | 46.62% |
| Gross Profit Growth % | 4.78% | 9.49% | 10.7% | 10.59% | -5.58% | 28.71% | 7.94% | 15.9% | 9% | - |
| Operating Expenses | 539.5M | 578.6M | 618.1M | 694.4M | 691.5M | 796.3M | 873M | 1.08B | 1.4B | 1.42B |
| OpEx % of Revenue | 33.48% | 32.77% | 32.61% | 33.5% | 34.79% | 32.93% | 34.5% | 36.31% | 41.48% | - |
| Selling, General & Admin | 390.5M | 415.9M | 444.7M | 504.8M | 477.8M | 562.3M | 607.4M | 729.4M | 893.8M | 931.1M |
| SG&A % of Revenue | 24.24% | 23.55% | 23.46% | 24.36% | 24.04% | 23.26% | 24% | 24.6% | 26.55% | - |
| Research & Development | 149M | 162.7M | 173.4M | 187.7M | 198M | 220.8M | 235.9M | 294.8M | 376.5M | 395.2M |
| R&D % of Revenue | 9.25% | 9.21% | 9.15% | 9.06% | 9.96% | 9.13% | 9.32% | 9.94% | 11.18% | - |
| Other Operating Expenses | 0 | 0 | 0 | 1.9M | 15.7M | 13.2M | 29.7M | 52.2M | 126.1M | 2M |
| Operating Income | 177.2M▲ 0% | 214.7M▲ 21.2% | 262.4M▲ 22.2% | 300.9M▲ 14.7% | 248.3M▼ 17.5% | 413.3M▲ 66.5% | 432.7M▲ 4.7% | 436.9M▲ 1.0% | 253.1M▼ 42.1% | 186.9M▲ 0% |
| Operating Margin % | 11% | 12.16% | 13.84% | 14.52% | 12.49% | 17.09% | 17.1% | 14.74% | 7.52% | 5.44% |
| Operating Income Growth % | 21.62% | 21.16% | 22.22% | 14.67% | -17.48% | 66.45% | 4.69% | 0.97% | -42.07% | - |
| EBITDA | 231.5M | 278.6M | 327.3M | 376.5M | 328.7M | 502.5M | 521.4M | 551.8M | 436.9M | 407.2M |
| EBITDA Margin % | 14.37% | 15.78% | 17.27% | 18.17% | 16.54% | 20.78% | 20.6% | 18.61% | 12.98% | 11.85% |
| EBITDA Growth % | 16.33% | 20.35% | 17.48% | 15.03% | -12.7% | 52.88% | 3.76% | 5.83% | -20.82% | -6.8% |
| D&A (Non-Cash Add-back) | 54.3M | 63.9M | 64.9M | 75.6M | 80.4M | 89.2M | 88.7M | 114.9M | 183.8M | 220.3M |
| EBIT | 207.8M | 235.6M | 275.2M | 296.4M | 240.2M | 407.9M | 430M | 560.6M | 254.8M | 95.7M |
| Net Interest Income | -12.9M | -14.6M | -11.4M | -14.7M | -11.2M | -13.4M | -13.3M | -8.9M | -38.6M | -56M |
| Interest Income | 300K | 800K | 1.2M | 1.3M | 3.2M | 900K | 2.8M | 7.5M | 9.3M | 10.4M |
| Interest Expense | 13.2M | 15.4M | 12.6M | 16M | 14.4M | 14.3M | 16.1M | 16.4M | 47.9M | 40.7M |
| Other Income/Expense | -4.2M | -21.7M | -17.7M | -20.5M | -22.5M | -19.7M | -17.8M | 109.3M | -47.9M | -165.9M |
| Pretax Income | 177.6M▲ 0% | 197.8M▲ 11.4% | 244.7M▲ 23.7% | 280.4M▲ 14.6% | 225.8M▼ 19.5% | 393.6M▲ 74.3% | 414.9M▲ 5.4% | 546.2M▲ 31.6% | 205.2M▼ 62.4% | 21M▲ 0% |
| Pretax Margin % | 11.02% | 11.2% | 12.91% | 13.53% | 11.36% | 16.28% | 16.39% | 18.42% | 6.1% | 0.61% |
| Income Tax | 23.1M | 117.5M | 63.7M | 82.4M | 64.4M | 113M | 116.4M | 117.7M | 91.4M | 29.3M |
| Effective Tax Rate % | 13.01% | 59.4% | 26.03% | 29.39% | 28.52% | 28.71% | 28.05% | 21.55% | 44.54% | 139.52% |
| Net Income | 153.6M▲ 0% | 78.6M▼ 48.8% | 179.7M▲ 128.6% | 197.2M▲ 9.7% | 157.8M▼ 20.0% | 277.1M▲ 75.6% | 296.6M▲ 7.0% | 427.2M▲ 44.0% | 113.1M▼ 73.5% | -8.6M▲ 0% |
| Net Margin % | 9.53% | 4.45% | 9.48% | 9.51% | 7.94% | 11.46% | 11.72% | 14.41% | 3.36% | -0.25% |
| Net Income Growth % | 51.18% | -48.83% | 128.63% | 9.74% | -19.98% | 75.6% | 7.04% | 44.03% | -73.53% | -107.6% |
| Net Income (Continuing) | 154.5M | 80.3M | 181M | 198M | 161.4M | 280.6M | 298.5M | 428.5M | 113.8M | -8.3M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 6.7M | 8.1M | 8.5M | 31.4M | 13.1M | 14.3M | 18M | 36.1M | 34M | 36.8M |
| EPS (Diluted) | 0.95▲ 0% | 0.49▼ 48.4% | 1.14▲ 132.7% | 1.26▲ 10.5% | 1.02▼ 19.0% | 1.81▲ 77.5% | 1.99▲ 9.9% | 2.90▲ 45.7% | 0.76▼ 73.8% | -0.06▲ 0% |
| EPS Growth % | 58.33% | -48.42% | 132.65% | 10.53% | -19.05% | 77.45% | 9.94% | 45.73% | -73.79% | -120% |
| EPS (Basic) | 0.95 | 0.50 | 1.15 | 1.27 | 1.03 | 1.83 | 2.00 | 2.92 | 0.76 | - |
| Diluted Shares Outstanding | 162.2M | 159.1M | 157.2M | 156.6M | 154.6M | 152.9M | 149.4M | 147.2M | 149.5M | 152.5M |
| Basic Shares Outstanding | 161.4M | 158.1M | 156.2M | 155.2M | 153.4M | 151.4M | 148.6M | 146.4M | 149M | 152M |
| Dividend Payout Ratio | 16.8% | 32.32% | 13.97% | 12.68% | 15.59% | 8.73% | 10.05% | 6.88% | 26.7% | - |
BRKR Balance Sheet
Bruker Corporation (BRKR) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 1.27B | 1.36B | 1.3B | 1.8B | 1.93B | 2.47B | 2.11B | 2.16B | 2.05B | 2.21B |
| Cash & Short-Term Investments | 500.3M | 439.2M | 322.4M | 684.9M | 731.8M | 1.17B | 645.5M | 488.3M | 183.4M | 298.8M |
| Cash Only | 342.4M | 325M | 322.4M | 678.3M | 681.8M | 1.07B | 645.5M | 488.3M | 183.4M | 298.8M |
| Short-Term Investments | 157.9M | 114.2M | 0 | 6.6M | 50M | 100M | 0 | 0 | 0 | 0 |
| Accounts Receivable | 243.9M | 319.3M | 357.2M | 362.2M | 335.3M | 416.9M | 595.3M | 621.8M | 701.2M | 544.9M |
| Days Sales Outstanding | 55.25 | 66 | 68.78 | 63.79 | 61.58 | 62.93 | 85.86 | 76.56 | 76.03 | 70.58 |
| Inventory | 440.4M | 486.2M | 509.6M | 577.2M | 692.3M | 710.1M | 800.1M | 968.3M | 1.07B | 1.09B |
| Days Inventory Outstanding | 185.02 | 186.23 | 186.83 | 195.56 | 241.19 | 214.51 | 238.4 | 243.54 | 227.01 | 230.11 |
| Other Current Assets | 91.3M | 114.1M | 115.1M | 172M | 165.6M | 176.6M | 29M | 30.3M | 39.6M | 274.2M |
| Total Non-Current Assets | 540.1M | 589.7M | 824.3M | 975.2M | 1.12B | 1.18B | 1.5B | 2.09B | 3.75B | 4.03B |
| Property, Plant & Equipment | 239.1M | 266.5M | 270.6M | 371.7M | 462.9M | 466M | 538.2M | 691.4M | 814.8M | 744.8M |
| Fixed Asset Turnover | 6.74x | 6.63x | 7.01x | 5.58x | 4.29x | 5.19x | 4.70x | 4.29x | 4.13x | 4.68x |
| Goodwill | 130.6M | 169.8M | 275.7M | 293M | 320.4M | 339.5M | 457.6M | 582.6M | 1.51B | 0 |
| Intangible Assets | 69.7M | 82.4M | 218.7M | 233.2M | 229.1M | 211.8M | 270.9M | 330.5M | 912.5M | 3.28B |
| Long-Term Investments | -93.1M | -71M | -59.3M | 0 | 0 | 0 | 0 | 0 | 0 | 7.9M |
| Other Non-Current Assets | 16.6M | 14M | 8.4M | 16.8M | 39.6M | 70.8M | 155.1M | 184M | 232.7M | 2.36B |
| Total Assets | 1.81B▲ 0% | 1.95B▲ 7.5% | 2.13B▲ 9.2% | 2.77B▲ 30.2% | 3.05B▲ 10.0% | 3.65B▲ 19.7% | 3.61B▼ 1.0% | 4.25B▲ 17.7% | 5.81B▲ 36.6% | 6.24B▲ 0% |
| Asset Turnover | 0.89x | 0.91x | 0.89x | 0.75x | 0.65x | 0.66x | 0.70x | 0.70x | 0.58x | 0.55x |
| Asset Growth % | 4.74% | 7.48% | 9.24% | 30.2% | 10.01% | 19.71% | -1.05% | 17.67% | 36.63% | 51.82% |
| Total Current Liabilities | 525.9M | 524.5M | 598M | 645.6M | 791.9M | 938.5M | 914.3M | 1.2B | 1.28B | 1.28B |
| Accounts Payable | 86.1M | 90.8M | 104.5M | 118.4M | 134.6M | 147.4M | 178.4M | 202.7M | 234.1M | 215.9M |
| Days Payables Outstanding | 36.17 | 34.78 | 38.31 | 40.12 | 46.89 | 44.53 | 53.16 | 50.98 | 49.77 | 44.17 |
| Short-Term Debt | 20.1M | 0 | 18.5M | 500K | 2.2M | 112.4M | 18.7M | 121.2M | 32.5M | 16.6M |
| Deferred Revenue (Current) | 149M | 111.7M | 124.4M | 240.5M | 307.2M | 335.9M | 370.2M | 400M | 438.2M | 1.39B |
| Other Current Liabilities | 269.8M | 256.3M | 288.5M | 119.5M | 121.3M | 156.4M | 159.9M | 218.3M | 300.3M | 605.4M |
| Current Ratio | 2.42x | 2.59x | 2.18x | 2.78x | 2.43x | 2.63x | 2.31x | 1.80x | 1.60x | 1.60x |
| Quick Ratio | 1.58x | 1.66x | 1.33x | 1.89x | 1.56x | 1.88x | 1.44x | 0.99x | 0.77x | 0.77x |
| Cash Conversion Cycle | 204.1 | 217.45 | 217.29 | 219.23 | 255.87 | 232.91 | 271.1 | 269.12 | 253.27 | 256.53 |
| Total Non-Current Liabilities | 593.9M | 690.5M | 625.5M | 1.19B | 1.28B | 1.63B | 1.57B | 1.63B | 2.71B | 2.45B |
| Long-Term Debt | 391.6M | 415.6M | 322.6M | 812.8M | 842.3M | 1.22B | 1.2B | 1.16B | 2.06B | 1.85B |
| Capital Lease Obligations | 0 | 1.3M | 7.1M | 47M | 47M | 41.8M | 34.8M | 74.8M | 118.9M | 18.9M |
| Deferred Tax Liabilities | 10.1M | 24.3M | 51.1M | 48.8M | 43.1M | 46M | 62.3M | 67.7M | 118.5M | 0 |
| Other Non-Current Liabilities | 145.4M | 200.6M | 182.5M | 236.3M | 299.5M | 266.9M | 166.5M | 240.2M | 311M | 2.7B |
| Total Liabilities | 1.12B | 1.22B | 1.22B | 1.83B | 2.07B | 2.57B | 2.48B | 2.84B | 3.99B | 3.73B |
| Total Debt | 411.7M | 415.6M | 341.1M | 880.9M | 912.8M | 1.39B | 1.27B | 1.38B | 2.25B | 1.87B |
| Net Debt | 69.3M | 90.6M | 18.7M | 202.6M | 231M | 325.7M | 624.9M | 891.3M | 2.06B | 1.57B |
| Debt / Equity | 0.59x | 0.56x | 0.37x | 0.94x | 0.94x | 1.28x | 1.12x | 0.98x | 1.24x | 1.24x |
| Debt / EBITDA | 1.78x | 1.49x | 1.04x | 2.34x | 2.78x | 2.77x | 2.44x | 2.50x | 5.14x | 4.59x |
| Net Debt / EBITDA | 0.30x | 0.33x | 0.06x | 0.54x | 0.70x | 0.65x | 1.20x | 1.62x | 4.72x | 4.72x |
| Interest Coverage | 13.42x | 13.94x | 20.83x | 18.81x | 17.24x | 28.90x | 26.88x | 26.64x | 5.28x | 2.35x |
| Total Equity | 699.8M▲ 0% | 741.6M▲ 6.0% | 913.6M▲ 23.2% | 938.2M▲ 2.7% | 974.3M▲ 3.8% | 1.08B▲ 11.3% | 1.13B▲ 4.3% | 1.41B▲ 24.9% | 1.82B▲ 28.4% | 2.51B▲ 0% |
| Equity Growth % | -5.39% | 5.97% | 23.19% | 2.69% | 3.85% | 11.34% | 4.33% | 24.87% | 28.44% | 103.44% |
| Book Value per Share | 4.31 | 4.66 | 5.81 | 5.99 | 6.30 | 7.09 | 7.58 | 9.60 | 12.14 | 16.46 |
| Total Shareholders' Equity | 693.1M | 733.5M | 905.1M | 906.8M | 961.2M | 1.07B | 1.11B | 1.38B | 1.78B | 2.47B |
| Common Stock | 1.7M | 1.7M | 1.7M | 1.7M | 1.7M | 1.7M | 1.7M | 1.7M | 1.8M | 2.47B |
| Retained Earnings | 885.2M | 942M | 1.1B | 1.27B | 1.41B | 1.66B | 1.93B | 2.32B | 2.41B | 0 |
| Treasury Stock | -249.3M | -401.2M | -401.5M | -543.8M | -667M | -820.3M | -1.08B | -1.24B | -1.24B | 0 |
| Accumulated OCI | -75.9M | 27M | 17M | -25.5M | 3.7M | -8.2M | 14.8M | 6M | -103.5M | 0 |
| Minority Interest | 6.7M | 8.1M | 8.5M | 31.4M | 13.1M | 14.3M | 18M | 36.1M | 34M | 36.8M |
BRKR Cash Flow Statement
Bruker Corporation (BRKR) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 130.8M | 154.4M | 239.7M | 213.4M | 332.2M | 282.4M | 274.4M | 350.1M | 251.3M | 251.3M |
| Operating CF Margin % | 8.12% | 8.74% | 12.65% | 10.3% | 16.71% | 11.68% | 10.84% | 11.81% | 7.46% | - |
| Operating CF Growth % | -42.93% | 18.04% | 55.25% | -10.97% | 55.67% | -14.99% | -2.83% | 27.59% | -28.22% | -11658.25% |
| Net Income | 154.5M | 80.3M | 181M | 198M | 161.4M | 280.6M | 298.5M | 427.2M | 113.8M | -8.6M |
| Depreciation & Amortization | 54.3M | 63.9M | 64.9M | 75.6M | 80.5M | 89.1M | 88.7M | 114.9M | 183.8M | 220.3M |
| Stock-Based Compensation | 9.4M | 11M | 11.3M | 9.6M | 16M | 17.2M | 27.7M | 24M | 25.3M | 0 |
| Deferred Taxes | -26.9M | 28.2M | -15.1M | -5.4M | -22.5M | -5.8M | -14.8M | -24.4M | -63.8M | -104.5M |
| Other Non-Cash Items | 24.1M | 11.6M | 39.8M | 10.1M | 27.2M | 26.5M | 18.4M | -103.8M | 70.4M | 214.6M |
| Working Capital Changes | -84.6M | -40.6M | -42.2M | -74.5M | 69.6M | -125.2M | -144.1M | -87.8M | -78.2M | -188M |
| Change in Receivables | -8.4M | -55.5M | -30.5M | -5M | 40.8M | -95.3M | -67.9M | -900K | -40.6M | 0 |
| Change in Inventory | -43.2M | -6.6M | -35.5M | -60.2M | -91.6M | -67M | -137.9M | -125M | -69.8M | 0 |
| Change in Payables | -19.6M | 33.7M | 6.2M | 15.9M | -2.4M | 61.8M | 33.3M | 23.1M | 20.8M | 0 |
| Cash from Investing | -21.8M | -30.2M | -123.4M | -158.4M | -192.7M | -192.4M | -251.6M | -326M | -1.76B | -196.5M |
| Capital Expenditures | -37.1M | -43.7M | -49.2M | -73M | -97.2M | -92M | -129.2M | -106.9M | -115.3M | -90.8M |
| CapEx % of Revenue | 2.3% | 2.47% | 2.6% | 3.52% | 4.89% | 3.81% | 5.11% | 3.61% | 3.43% | - |
| Acquisitions | -24.3M | -66.3M | -191.6M | -90M | -59.2M | -65M | -182.3M | -226.6M | -1.6B | -73.9M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 1.1M | 11.5M | 118.9M | 11M | 200K | 4.9M | 13.9M | 11.1M | 1.1M | -31.8M |
| Cash from Financing | -27.2M | -159M | -112.4M | 300M | -161.6M | 318.7M | -415.3M | -193.4M | 1.23B | 135.1M |
| Debt Issued (Net) | 145.9M | 3.1M | -93.5M | 467M | -8.3M | 489.7M | -110.7M | -21.5M | 875.9M | -491.9M |
| Equity Issued (Net) | -1000K | -1000K | 1000K | -1000K | -1000K | -1000K | -1000K | -1000K | 1000K | -2.4M |
| Dividends Paid | -25.8M | -25.4M | -25.1M | -25M | -24.6M | -24.2M | -29.8M | -29.4M | -30.2M | -32.9M |
| Share Repurchases | -160M | -152.2M | 0 | -142.3M | -123.2M | -153.3M | -263.1M | -152.3M | 0 | -10M |
| Other Financing | 12.7M | 15.5M | -3.2M | -10.6M | -8.8M | -500K | -11.7M | 300K | -18.9M | 671.1M |
| Net Change in Cash | 75.3M▲ 0% | -17M▼ 122.6% | -2.6M▲ 84.7% | 355.6M▲ 13776.9% | 3.6M▼ 99.0% | 386.2M▲ 10627.8% | -423M▼ 209.5% | -157.1M▲ 62.9% | -304.9M▼ 94.1% | 116.4M▲ 0% |
| Free Cash Flow | 93.7M▲ 0% | 110.7M▲ 18.1% | 190.5M▲ 72.1% | 140.4M▼ 26.3% | 235M▲ 67.4% | 190.4M▼ 19.0% | 145.2M▼ 23.7% | 243.2M▲ 67.5% | 136M▼ 44.1% | 43.3M▲ 0% |
| FCF Margin % | 5.82% | 6.27% | 10.05% | 6.77% | 11.82% | 7.87% | 5.74% | 8.2% | 4.04% | 1.26% |
| FCF Growth % | -51.95% | 18.14% | 72.09% | -26.3% | 67.38% | -18.98% | -23.74% | 67.49% | -44.08% | -68.16% |
| FCF per Share | 0.58 | 0.70 | 1.21 | 0.90 | 1.52 | 1.25 | 0.97 | 1.65 | 0.91 | 0.91 |
| FCF Conversion (FCF/Net Income) | 0.85x | 1.96x | 1.33x | 1.08x | 2.11x | 1.02x | 0.93x | 0.82x | 2.22x | -5.03x |
| Interest Paid | 12.5M | 15.2M | 11.7M | 16M | 28.7M | 19.6M | 24.3M | 33.7M | 54.6M | 14.7M |
| Taxes Paid | 72.4M | 53.1M | 60.5M | 61.3M | 43M | 145.5M | 147.4M | 96.6M | 153.9M | 38.7M |
BRKR Key Ratios
Bruker Corporation (BRKR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 21.34% | 10.91% | 21.71% | 21.3% | 16.5% | 26.91% | 26.76% | 33.57% | 7.01% | -0.34% |
| Return on Invested Capital (ROIC) | 17.62% | 20.11% | 22.31% | 21.77% | 15.88% | 23.7% | 20.49% | 16.14% | 6.14% | 6.14% |
| Gross Margin | 46.08% | 46.04% | 47.48% | 48.02% | 47.29% | 50.03% | 51.59% | 51.05% | 49% | 46.62% |
| Net Margin | 9.53% | 4.45% | 9.48% | 9.51% | 7.94% | 11.46% | 11.72% | 14.41% | 3.36% | -0.25% |
| Debt / Equity | 0.59x | 0.56x | 0.37x | 0.94x | 0.94x | 1.28x | 1.12x | 0.98x | 1.24x | 1.24x |
| Interest Coverage | 13.42x | 13.94x | 20.83x | 18.81x | 17.24x | 28.90x | 26.88x | 26.64x | 5.28x | 2.35x |
| FCF Conversion | 0.85x | 1.96x | 1.33x | 1.08x | 2.11x | 1.02x | 0.93x | 0.82x | 2.22x | -5.03x |
| Revenue Growth | -0.77% | 9.59% | 7.34% | 9.34% | -4.11% | 21.66% | 4.67% | 17.14% | 13.56% | 2.08% |
BRKR SEC Filings & Documents
Bruker Corporation (BRKR) SEC filings — annual & quarterly reports (10-K, 10-Q)
BRKR Frequently Asked Questions
Bruker Corporation (BRKR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Bruker Corporation (BRKR) reported $3.44B in revenue for fiscal year 2024. This represents a 5212% increase from $64.7M in 1999.
Bruker Corporation (BRKR) grew revenue by 13.6% over the past year. This is steady growth.
Bruker Corporation (BRKR) reported a net loss of $8.6M for fiscal year 2024.
Dividend & Returns
Yes, Bruker Corporation (BRKR) pays a dividend with a yield of 0.53%. This makes it attractive for income-focused investors.
Bruker Corporation (BRKR) has a return on equity (ROE) of 7.0%. This is below average, suggesting room for improvement.
Bruker Corporation (BRKR) generated $43.3M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More BRKR
Bruker Corporation (BRKR) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates